RT Journal Article
T1 Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.
A1 Bellido, Virginia
A1 Martínez, Julia
A1 Calvo, Fernando
A1 Villarroel, Aida
A1 Lecumberri, Edurne
A1 Moreno, Juan
A1 Morillas, Carlos
A1 Rodrigo, Silvia
A1 Izarra, Aitziber
A1 Lecube, Albert
K1 Cardiometabolic risk factors
K1 Dapagliflozin
K1 Diabetes mellitus
K1 Diabetic angiopathy
K1 Sodium-glucose cotransporter 2 inhibitors
K1 Therapeutic inertia
AB Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is associated with reductions in blood pressure and weight, and promotes a favourable lipid profile. In this review, we address the impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate its potential beneficial effects on other less frequent complications of diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i in clinical practice is discussed. Our goal is to help translate this evidence into clinical practice.
SN 1869-6953
YR 2022
FD 2022-03-25
LK http://hdl.handle.net/10668/21374
UL http://hdl.handle.net/10668/21374
LA en
DS RISalud
RD Apr 8, 2025